NASDAQ · CLDX
Celldex Therapeutics, Inc.
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
Loading market information…
NASDAQ · CBIO · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Crescent Biopharma, Inc.’s forward annual dividend is $96.00 per share, paid quarterly. The forward yield is 682.3% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Crescent Biopharma, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.67. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Crescent Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 14, 2025 |
| -$0.04+99.2% vs estimate |
| $0.00 |
| Q4 2024 | Feb 13, 2025 | -$0.11+31.25% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.15-36.36% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $36.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
$18.61+$0.22 (+1.2%)
Arcus Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.37% below the high.
$28.71-$0.19 (-0.66%)
Zymeworks Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.39% below the high.
$2.29-$0.07 (-2.97%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.11% below the high.
$2.04+$0.03 (+1.49%)
Compugen Ltd.’s quoted price sits in the lower half of its reported 52-week range, 37.04% below the high.
$1.13+$0.15 (+15.31%)
Veraxa Biotech Holding AG’s quoted price sits in the lower half of its reported 52-week range, 95.87% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$1.21-$0.05 (-3.97%)
NovaBridge Biosciences’s quoted price sits in the lower half of its reported 52-week range, 76.69% below the high.
